Surgical and oncological outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma
- 21 January 2025
- journal article
- research article
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 137 (7-8) , 244-245
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Our approach for out-of-center initiation of extracorporeal membrane oxygenation and subsequent interhospital transportWiener klinische Wochenschrift, 2024
- Surgical and oncological outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesotheliomaWiener klinische Wochenschrift, 2024
- ASO Author Reflections: Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelioma: Insights from a Multi-center StudyAnnals of Surgical Oncology, 2024
- Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelioma: Insights From a Multi-Center StudyAnnals of Surgical Oncology, 2024
- Morbidity and mortality of patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapyDiscover Oncology, 2024
- Outcomes following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancies: 10 Year experienceThe American Journal of Surgery, 2024
- The impact of the extent of surgery on late adverse effects following cytoreductive surgery and HIPECEuropean Journal of Surgical Oncology, 2023
- Principles of Surgical Management of Peritoneal MesotheliomaJournal of the National Comprehensive Cancer Network, 2023
- Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Outcomes and Survival From an Australian CentreAnticancer Research, 2022